This study indicates that surfactant replacement therapy with CHF5633 improves lung function and lung architecture, and attenuates inflammation in severe ARDS in adult rabbits similarly to Poractant alfa. Clinical trials have so far not yielded conclusive results, but exogenous surfactant may be a valid supportive treatment for patients with ARDS given its anti-inflammatory and lung-protective effects.
Keyphrases
- lung function
- acute respiratory distress syndrome
- replacement therapy
- extracorporeal membrane oxygenation
- mechanical ventilation
- cystic fibrosis
- chronic obstructive pulmonary disease
- air pollution
- clinical trial
- anti inflammatory
- smoking cessation
- early onset
- oxidative stress
- intensive care unit
- randomized controlled trial
- young adults
- combination therapy
- study protocol